Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Markovets, Aleksandra A.
15  Ergebnisse:
OpenAccess-Volltexte X
Personensuche X
?
1

Targeting melanoma's MCL1 bias unleashes the apoptotic pote..:

Sale, Matthew J ; Minihane, Emma ; Monks, Noel R...
doi:10.17863/CAM.59964.  , 2020
Link: https://doi.org/10.17863..
 
?
2

Targeting melanoma's MCL1 bias unleashes the apoptotic pote..:

Sale, Matthew J ; Minihane, Emma ; Monks, Noel R...
doi:10.17863/CAM.47074.  , 2019
Link: https://doi.org/10.17863..
 
?
3

Programmed Cell Death Ligand 1 Expression in Untreated EGFR..:

Brown, Helen ; Vansteenkiste, Johan ; Nakagawa, Kazuhiko...
http://hdl.handle.net/10668/14645.  , 2019
Link: http://hdl.handle.net/10..
 
?
4

Osimertinib as first-line treatment of EGFR mutation-positi..:

Ramalingam, Suresh S ; Yang, James C. -H ; Lee, Chee Khoon...
Journal of Clinical Oncology, Vol.36 No.9, pp.841-849.  , 2018
Link: http://hdl.handle.net/10..
 
?
5

VarDict: a novel and versatile variant caller for next-gene..:

Lai, Zhongwu ; Markovets, Aleksandra ; Ahdesmaki, Miika...
http://eprints.gla.ac.uk/122577/1/122577.pdf.  , 2016
Link: http://eprints.gla.ac.uk..
 
?
6

Analysis of cancer metabolism with high-throughput technolo..:

Herman Damir ; Markovets Aleksandra A
https://doaj.org/toc/1471-2105.  , 2011
Link: https://doi.org/10.1186/..
 
?
7

Analysis of cancer metabolism with high-throughput technolo..:

Markovets, Aleksandra A ; Herman, Damir
http://www.biomedcentral.com/1471-2105/12/S10/S8.  , 2011
Link: http://www.biomedcentral..
 
?
8

Promoter prediction in E. coli based on SIDD profiles and A..:

Bland, Charles ; Newsome, Abigail S ; Markovets, Aleksandra A
http://www.biomedcentral.com/1471-2105/11/S6/S17.  , 2010
Link: http://www.biomedcentral..
 
?
9

Promoter prediction in E. coli based on SIDD profiles and A..:

Markovets Aleksandra A ; Newsome Abigail S ; Bland Charles
https://doaj.org/toc/1471-2105.  , 2010
Link: https://doi.org/10.1186/..
 
?
10

Candidate mechanisms of acquired resistance to first-line o..:

Juliann Chmielecki ; Jhanelle E. Gray ; Ying Cheng...
https://doi.org/10.1038/s41467-023-35961-y.  , 2023
Link: https://doi.org/10.1038/..
 
?
11

Author Correction: Candidate mechanisms of acquired resista..:

Juliann Chmielecki ; Jhanelle E. Gray ; Ying Cheng...
https://doi.org/10.1038/s41467-023-38999-0.  , 2023
Link: https://doi.org/10.1038/..
 
?
12

The landscape of therapeutic vulnerabilities in EGFR inhibi..:

Steven W. Criscione ; Matthew J. Martin ; Derek B. Oien...
https://doi.org/10.1038/s41698-022-00337-w.  , 2022
Link: https://doi.org/10.1038/..
 
?
13

Molecular landscape of osimertinib resistance in patients a..:

Sun Min Lim ; San-Duk Yang ; Sangbin Lim...
https://doi.org/10.1177/17588359221079125.  , 2022
Link: https://doi.org/10.1177/..
 
?
14

Clinical impact of subclonal EGFR T790M mutations in advanc..:

Tereza Vaclova ; Ursula Grazini ; Lewis Ward...
https://doi.org/10.1038/s41467-021-22057-8.  , 2021
Link: https://doi.org/10.1038/..
 
?
15

Targeting melanoma's MCL1 bias unleashes the apoptotic pote..:

Matthew J. Sale ; Emma Minihane ; Noel R. Monks...
https://doi.org/10.1038/s41467-019-12409-w.  , 2019
Link: https://doi.org/10.1038/..
 
1-15